Se connecter Inscription gratuite

Last updated: 4 June 2024 at 4:42pm EST

David Stump Net Worth




The estimated Net Worth of David C Stump is at least $381 millier dollars as of 20 May 2024. David Stump owns over 4,500 units of Regenxbio Inc stock worth over $57,195 and over the last 18 years he sold RGNX stock worth over $0. In addition, he makes $323,316 as Independent Director at Regenxbio Inc.

David Stump RGNX stock SEC Form 4 insiders trading

David has made over 1 trades of the Regenxbio Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 4,500 units of RGNX stock worth $57,195 on 20 May 2024.

The largest trade he's ever made was exercising 4,500 units of Regenxbio Inc stock on 20 May 2024 worth over $57,195. On average, David trades about 94 units every 0 days since 2006. As of 20 May 2024 he still owns at least 4,500 units of Regenxbio Inc stock.

You can see the complete history of David Stump stock trades at the bottom of the page.





David Stump biography

Dr. David C. Stump M.D. serves as Independent Director of the Company. He has been a Director since October 2015. From November 1999 to December 2012, Dr. Stump was with Human Genome Sciences, Inc., a biopharmaceutical company, as Executive Vice President, Research and Development from May 2007 to December 2012, Executive Vice President, Drug Development from December 2003 to May 2007 and Senior Vice President, Drug Development from November 1999 to December 2003. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., a biopharmaceutical company, from 1989 to 1999, including Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump has served as a member of the boards of directors at Sunesis Pharmaceuticals, Inc. since June 2006, MacroGenics, Inc. since September 2013 and Portola Pharmaceuticals, Inc. since September 2015, each of which is a publicly held biopharmaceutical company. He also currently serves on the board of trustees of Earlham College. Dr. Stump previously served as a director at Dendreon Corporation, a biotechnology company, from June 2010 to June 2015. Dr. Stump holds an A.B. from Earlham College and an M.D. from Indiana University and completed his residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa. Dr. Stump has specific attributes that qualify him to continue to serve as a member of the Board, including his substantial medical and scientific background and expertise, his extensive experience in research and development and operations in the biotechnology industry and his prior service on public company boards.

What is the salary of David Stump?

As the Independent Director of Regenxbio Inc, the total compensation of David Stump at Regenxbio Inc is $323,316. There are 13 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.



How old is David Stump?

David Stump is 70, he's been the Independent Director of Regenxbio Inc since 2015. There are 1 older and 18 younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.

What's David Stump's mailing address?

David's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.

Insiders trading at Regenxbio Inc

Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas et Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.



What does Regenxbio Inc do?

regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.



What does Regenxbio Inc's logo look like?

Regenxbio Inc logo

Complete history of David Stump stock trades at Macrogenics Inc, Portola Pharmaceuticals, Regenxbio Inc et Sunesis Pharmaceuticals Inc

Date
#
Société
 Initié
Trans.
Transaction
 Actions Prix par action Prix ​​total Actions après Source
20 May 2024 MGNX Macrogenics Inc David C Stump
Directeur
 Exercice d'option 4,500 $4.26 $19,170
20 May 2024
4,500 ↗


Regenxbio Inc executives and stock owners

Regenxbio Inc executives and other stock owners filed with the SEC include: